Alx Oncology Holdings Inc (ALXO) Stock Price, Quote & News

Company Profile

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 466 7125

Website: www.alxoncology.com

Address:

323 Allerton Avenue, South San Francisco, United States

Carico13 Jul. 9 at 6:27 PM

$ALXO power hour rally? Consolidation around .50, holding the line in a red market

0 · Reply

Carico13 Jul. 9 at 5:34 PM

$ALXO 17% short interest float, lets get that short squeeze and burn them bears 🔥

2 · Reply

Carico13 Jul. 9 at 5:20 PM

$ALXO 🔥 $ALXO — Major catalyst on deck! Top-line data from ASPEN-06 Phase 2 trial (evorpacept + Herceptin + chemo in HER2+ gastric cancer) expected Q3 2025. 🚨 High unmet need 💊 Strong partnership with Zymeworks 📈 Low float, insider buying ⚠️ Market sleeping on it? If data hits, this goes vertical. 🚀

0 · Reply

mello_yello Jul. 9 at 4:52 PM

$ALXO Golden X primed!

1 · Reply

bobwut12 Jul. 9 at 12:15 AM

$ALXO Any upcoming catalysts for the rest of the summer?

0 · Reply

JrNannies Jul. 7 at 2:53 PM

$ALXO is axlo ever gonna hit MOASS squeezer type $$$

0 · Reply

Golibajje Jul. 1 at 12:27 AM

$ALXO Even this company is dead.. they knew atleast 2 years back that Evorpacept won’t work! Both as*holes Jason and Pons continued in order to rob cash

1 · Reply

Bionco Jun. 30 at 9:01 PM

$ALXO Another anti-CD47 Ab (Pfizer) is dead

0 · Reply

AsianAmericanPsycho Jun. 27 at 9:02 PM

$ALXO 5 million shares total trading after hours? whats going on here?

3 · Reply

Golibajje Jun. 27 at 7:41 PM

$ALXO Sell the f*cking company u as@hole Jason!!

1 · Reply

ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference

May 20, 2025, 8:00 AM EDT - 7 weeks ago

ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event

May 13, 2025, 8:00 AM EDT - 2 months ago

ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025

May 8, 2025, 8:30 AM EDT - 2 months ago

ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 2, 2025, 8:00 AM EDT - 2 months ago

ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 25, 2025, 1:10 PM EDT - 2 months ago

ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma

Apr 25, 2025, 9:00 AM EDT - 2 months ago

ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints

Mar 6, 2025, 4:01 PM EST - 4 months ago

ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 5, 2025, 8:00 AM EST - 4 months ago

ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event

Feb 27, 2025, 8:00 AM EST - 4 months ago

ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Feb 18, 2025, 8:00 AM EST - 5 months ago

ALX Oncology to Host Virtual R&D Day on March 5, 2025

Jan 23, 2025, 8:00 AM EST - 6 months ago

ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer

Jan 22, 2025, 4:01 PM EST - 6 months ago

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

Jan 21, 2025, 5:00 PM EST - 6 months ago

ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI

Dec 18, 2024, 8:00 AM EST - 7 months ago

ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium

Nov 14, 2024, 8:00 AM EST - 8 months ago

ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer

Nov 7, 2024, 4:00 PM EST - 8 months ago

ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 1, 2024, 5:30 PM EDT - 9 months ago

ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024

Sep 11, 2024, 10:36 PM EDT - 10 months ago

ALX Oncology's Evorpacept Gains Momentum With FDA Fast Track Designations

Aug 6, 2024, 4:01 PM EDT - 1 year ago

ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors

Jul 31, 2024, 4:01 PM EDT - 1 year ago

ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer

Jul 31, 2024, 5:30 AM EDT - 1 year ago

ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

Jun 27, 2024, 4:13 AM EDT - 1 year ago

ALX Oncology: Finally Reaching A Reasonable Buy-In Valuation

Jun 2, 2024, 10:00 AM EDT - 1 year ago

ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer

May 29, 2024, 9:00 AM EDT - 1 year ago

ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference

May 9, 2024, 4:00 PM EDT - 1 year ago

ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 7, 2024, 9:00 AM EDT - 1 year ago

ALX Oncology Appoints Allison Dillon as Chief Business Officer

Apr 24, 2024, 10:00 AM EDT - 1 year ago

ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting

$ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)$

Apr 9, 2024, 5:30 PM EDT - 1 year ago

ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)

Mar 7, 2024, 4:03 PM EST - 1 year ago

ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 5, 2024, 4:30 PM EST - 1 year ago

ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting

Dec 8, 2023, 8:30 AM EST - 1 year ago

ALX Oncology shares jump 9% after Jefferies upgrade

Nov 13, 2023, 4:05 PM EST - 1 year ago

ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Oct 10, 2023, 4:05 PM EDT - 1 year ago

ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Oct 9, 2023, 12:38 AM EDT - 1 year ago

ALX Oncology: On Right Track With Latest Interim Analysis Of Evorpacept

Oct 5, 2023, 8:00 AM EDT - 1 year ago

ALX Oncology Announces Pricing of Public Offering

Oct 4, 2023, 4:10 PM EDT - 1 year ago

ALX Oncology Announces Proposed Public Offering

Oct 3, 2023, 6:00 AM EDT - 1 year ago

ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

Oct 2, 2023, 4:05 PM EDT - 1 year ago

ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

Sep 6, 2023, 8:00 AM EDT - 2 years ago

ALX Oncology Realigns Executive Leadership Team

Aug 31, 2023, 7:00 AM EDT - 2 years ago

ALX Oncology Announces September Investor Conference Participation

Aug 10, 2023, 4:01 PM EDT - 2 years ago

ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update

Jun 26, 2023, 7:00 AM EDT - 2 years ago

ALX Oncology Receives Orphan Drug Designation from the European Commission for Evorpacept for the Treatment of Patients with Gastric Cancer

May 11, 2023, 4:01 PM EDT - 2 years ago

ALX Oncology Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

May 9, 2023, 7:00 AM EDT - 2 years ago

ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Patients with Ovarian Cancer

Mar 14, 2023, 8:00 AM EDT - 2 years ago

ALX Oncology and Quantum Leap Healthcare CollaborativeTM Announce First Patient Dosed in the I-SPY-P1 TRIAL in Breast Cancer

Mar 13, 2023, 7:00 AM EDT - 2 years ago

ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce First Patient Dosed in the I-SPY-P1 TRIAL in Breast Cancer

Mar 9, 2023, 4:01 PM EST - 2 years ago

ALX Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones

Feb 16, 2023, 7:00 AM EST - 2 years ago

ALX Oncology Announces First Patient Dosed in ASPEN-07, a Phase 1 Study of Evorpacept for the Treatment of Patients with Urothelial Cancer

Jan 5, 2023, 7:00 AM EST - 2 years ago

ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2023

Carico13 Jul. 9 at 6:27 PM

$ALXO power hour rally? Consolidation around .50, holding the line in a red market

0 · Reply

Carico13 Jul. 9 at 5:34 PM

$ALXO 17% short interest float, lets get that short squeeze and burn them bears 🔥

2 · Reply

Carico13 Jul. 9 at 5:20 PM

0 · Reply

mello_yello Jul. 9 at 4:52 PM

$ALXO Golden X primed!

1 · Reply

bobwut12 Jul. 9 at 12:15 AM

$ALXO Any upcoming catalysts for the rest of the summer?

0 · Reply

JrNannies Jul. 7 at 2:53 PM

$ALXO is axlo ever gonna hit MOASS squeezer type $$$

0 · Reply

Golibajje Jul. 1 at 12:27 AM

$ALXO Even this company is dead.. they knew atleast 2 years back that Evorpacept won’t work! Both as*holes Jason and Pons continued in order to rob cash

1 · Reply

Bionco Jun. 30 at 9:01 PM

$ALXO Another anti-CD47 Ab (Pfizer) is dead

0 · Reply

AsianAmericanPsycho Jun. 27 at 9:02 PM

$ALXO 5 million shares total trading after hours? whats going on here?

3 · Reply

Golibajje Jun. 27 at 7:41 PM

$ALXO Sell the f*cking company u as@hole Jason!!

1 · Reply

JrNannies Jun. 27 at 3:42 PM

$ALXO when is this news expected to come out

1 · Reply

Andrebrx1 Jun. 26 at 7:25 PM

$ALXO if Aspen-06 has positive updates this can stock likely goes 5x-10x higher but if the results are negative, it's very likely that this will drop temporarily to 10-15 cents. I like my chances here , they have cash until mid 2026

1 · Reply

bullbuster269 Jun. 26 at 2:52 PM

$GTBP $ALXO $ERAS $MOLN $SLDB

0 · Reply

AsianAmericanPsycho Jun. 25 at 4:14 PM

$ALXO How does this stock have 18.5% short interest and supposedly 20 days to cover when nobody is buying? The fuck?!

0 · Reply

AsianAmericanPsycho Jun. 25 at 11:49 AM

$ALXO Is it a ghost town in this bitch or what?

0 · Reply

Andrebrx1 Jun. 23 at 7:08 PM

$ALXO im doubling down here, this is way undervalued

0 · Reply

nooooooooooooo0ooo Jun. 23 at 1:38 PM

$ALXO There will be bad results for Breast cancer, Jason is POS.

1 · Reply

BiopharmaWatch_com Jun. 16 at 6:14 PM

🚀 Hot IND Filings Ahead! 🚀 Watch these biotech plays gearing up for IND filings in H1 & Mid-2025: • $GTBP GTB-5550 (solid tumors) – PoA 10% • $ALXO ALX2004 (EGFR ADC) – PoA 25% • $ERAS ERAS-0015 (NRAS melanoma) – PoA 12% • $MOLN MP0712 (DLL3 target) – PoA 12% • $SLDB SGT-501 (gene therapy for CPVT) – PoA 30% Early-stage catalysts worth tracking for potential moves! Get full details & real-time updates at biopharmawatch.com #Biotech #INDFilings #Catalysts #BiotechInvesting

0 · Reply

Andrebrx1 Jun. 11 at 4:18 PM

$ALXO catalyst soon

0 · Reply

P119 Jun. 4 at 1:17 AM

$ALXO moving to 2$ or squeeze upper?

0 · Reply

Arthur_PL May. 30 at 9:35 PM

$ALXO it's interesting reading https://finance.yahoo.com/quote/ALXO/community/

0 · Reply

nooooooooooooo0ooo May. 30 at 9:39 AM

$ALXO what the fc is going on

0 · Reply

Market Cap	25.76M
Revenue (ttm)	0.00
Net Income (ttm)	-134.85M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.11

Volume	282,100
Avg Vol	513,892
Day's Range	N/A - N/A
Shares Out	53.40M
Stochastic %K	60%
Beta	1.11
Analysts	Strong Sell
Price Target	$2.25